Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): commentary, Joks et al.
Gero Joks, Steve Su, Jarrad King
The British journal of psychiatry : the journal of mental science November 1, 2024 DOI: 10.1192/bjp.2024.79 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Randomized Double-blind Peer reviewed |
|---|---|
| Topics | Depression Esketamine Ketamine |
| Keywords | Depression/mental health/mental illness Ketamine/esketamine/psychedelics Treatment-resistant depression/trd/refractory depression |
| Key points | Argues that the KADS trial's use of midazolam as an active control may not adequately mask ketamine's effects, and that the 4-week duration limits conclusions about long-term efficacy and safety. |
Abstract
Regarding the article, 'Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial', we commend Loo et al for undertaking the Ketamine for Adult Depression Study (KADS). In the interest of ensuring that accurate and balanced information is presented to healthcare professionals on treatment-resistant depression, we raise several points herein to help clarify and provide additional perspective to the researchers' interpretation of their findings in the Discussion.